[1] Wang S,Shangguan Y, Ding C, et al. Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury.J Int Med Res, 2020, 48: 300060518811512.
[2] Rolf T. Idiosyncratic DILI: analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019.Front Pharmacol, 2019, 10: 730.
[3] Danan G,Teschke R.Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?.Drug Saf, 2018, 41: 735-743.
[4] Zhang D,Hao J,Hou R, et al. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients .J Clin Pharm Ther, 2020, 45: 561-569.
[5] Yuliwulandari R, Susilowati RW, Wicaksono BD, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis .J Hum Genet, 2016, 61: 533-537.
[6] Suvichapanich S, Fukunaga K, Zahroh H, et al. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.Pharmacogenet Genomics, 2018, 28: 167-176.
[7] Guengerich FP.Cytochrome P450 2E1 and its roles in disease.Chem Biol Interact, 2020, 322: 109056.
[8] Yang S, Hwang SJ, Park JY, et al. CYP2E1, NAT2, GSTAssociation of genetic polymorphisms of and with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.BMJ Open, 2019, 9: e027940.
[9] Zhang M,Wu SQ, He JQ.Are genetic variations in glutathione S-transferases involved in anti-tuberculosis drug-induced liver injury? a meta-analysis .J Clin Pharm Ther, 2019, 44: 844-857.
[10] Wu S, Wang YJ, Tang X, et al. Genetic polymorphisms of glutathione S-transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity.PLoS ONE, 2016, 11: e0157478.
[11] Lv X,Xia Y,Finel M, et al. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors .Acta Pharm Sin B, 2019, 9: 258-278.
[12] Sun Q, Liu HP, Zheng RJ, et al. Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a chinese population-based prospective case-control study. Clin Drug Investig, 2017, 37: 1125-1136.
[13] Lee HH, Ho RH.Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).Br J Clin Pharmacol, 2017, 83: 1176-1184.
[14] Chen S, Pan H, Chen Y et al. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study .Sci Rep, 2019, 9: 14311.
[15] Zhang J, Zhao Z, Bai H, et al. Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury .PLoS ONE, 2019, 14: e0222033.
[16] Fasching CL.Telomere length measurement as a clinical biomarker of aging and disease .Crit Rev Clin Lab Sci, 2018, 55: 443-465.
[17] Udomsinprasert W, Chanhom N, Suvichapanich S, et al. Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury .Sci Rep, 2020, 10: 5628.
[18] Deng Q,Huang W,Peng C, et al.Genomic 5-mC contents in peripheral blood leukocytes were independent protective factors for coronary artery disease with a specific profile in different leukocyte subtypes .Clin Epigenetics, 2018, 10: 9.
[19] Li Y,Ren Q,Wu D, et al.Combined 5-hydroxymethylcytosine content of human leucocyte antigen-B and human leucocyte antigen-DQB1 as novel biomarker for anti-tuberculosis drug-induced liver injury.Basic Clin Pharmacol Toxicol, 2020.
[20] Norouzi M,Yasamineh S, Montazeri M, et al. Recent advances on nanomaterials-based fluorimetric approaches for microRNAs detection .Mater Sci Eng C Mater Biol Appl, 2019, 104: 110007.
[21] Howell LS,Ireland L,Park BK, et al.MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury .Expert Rev Mol Diagn, 2018,18: 47-54.
[22] Song L, Zhang Z, Zhang J, et al.Ratio of microRNA-122/155 in isoniazid-induced acute liver injury in mice.Exp Ther Med, 2016, 12: 889-894.
[23] Krijt J,Sokolováj, Ješinp, et al.Activity of the liver enzyme ornithine carbamoyltransferase (OCT) in blood: LC-MS/MS assay for non-invasive diagnosis of ornithine carbamoyltransferase deficiency .Clin Chem Lab Med, 2017, 55: 1168-1177.
[24] Furihata T, Aizawa T, Koibuchi A, et al. Characterization of release profile of ornithine carbamoyltransferase from primary rat hepatocytes treated with hepatotoxic drugs: implications for its unique potential as a drug-induced liver injury biomarker .Drug Metab Pharmacokinet, 2016, 31: 102-105.
[25] Shen T, Gu D, Zhu Y, et al.The value of eosinophil VCS parameters in predicting hepatotoxicity of antituberculosis drugs .Int J Lab Hematol, 2016, 38: 514-519. |
